A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)

Study Summary

SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Interventions

Study Locations

Facility	City	State	Country
City of Hope	Duarte	California	United States
Stanford Cancer Institute	Palo Alto	California	United States
Northside Hospital	Atlanta	Georgia	United States
University of Kansas Medical Center	Fairway	Kansas	United States
Karmanos Cancer Institute	Detroit	Michigan	United States
University of Nebraska Medical Center	Omaha	Nebraska	United States
MD Anderson Cancer Center	Houston	Texas	United States
Royal Adelaide Hospital	Adelaide	South Australia	Australia
Peter MacCallum Cancer Centre	Melbourne	Victoria	Australia
Linear Clinical Research Ltd	Nedlands	Western Australia	Australia

Official Trial Information

View on ClinicalTrials.gov